William Brinkerhoff, EVOQ Therapeutics CEO
January 3, 2023 10:19 AM ESTUpdated 11:06 AM
Startups
Deals

Af­ter dis­as­trous Gala­pa­gos deal, Gilead finds new rheuma­toid arthri­tis part­ner

Kyle LaHucik

Senior Reporter

Gilead is look­ing for an­oth­er shot at treat­ing rheuma­toid arthri­tis af­ter its mas­sive Gala­pa­gos deal fell flat in the face of an FDA re­jec­tion and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times